Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVMXY AVITA MED LTD/S	$7.89	$7.89	$1.06 ▼ $8.58	$651.87M	1.28	183,275 shs	N/A
BCRX BioCryst Pharmaceuticals	$10.73 -1.4%	$8.66	$5.92 ▼ $11.11	$2.25B	1.08	3.01 million shs	3.22 million shs
IBRX ImmunityBio	$2.67 +2.7%	$2.61	$1.83 ▼ $7.63	$2.36B	0.33	5.62 million shs	9.44 million shs
IMVT Immunovant	$14.87 -0.1%	$14.99	$12.72 ▼ $34.47	$2.53B	0.75	1.19 million shs	1.46 million shs

Free Today: Your Guide to Smarter Options Trades

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVMXY AVITA MED LTD/S	0.00%	0.00%	0.00%	0.00%	0.00%
BCRX BioCryst Pharmaceuticals	0.00%	+1.32%	+20.16%	+25.64%	+66.10%
IBRX ImmunityBio	0.00%	+5.53%	+5.12%	-6.32%	-58.41%
IMVT Immunovant	0.00%	+2.84%	-5.89%	-19.36%	-41.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVMXY AVITA MED LTD/S	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BCRX BioCryst Pharmaceuticals	4.4447 of 5 stars	4.4	1.0	0.0	4.2	4.0	1.7	0.6
IBRX ImmunityBio	2.2752 of 5 stars	3.6	1.0	0.0	0.0	3.2	1.7	0.6
IMVT Immunovant	2.2422 of 5 stars	4.5	0.0	0.0	0.0	2.8	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVMXY AVITA MED LTD/S	0.00	N/A	N/A	N/A
BCRX BioCryst Pharmaceuticals	2.89	Moderate Buy	$16.56	54.29% Upside
IBRX ImmunityBio	3.20	Buy	$12.25	358.80% Upside
IMVT Immunovant	2.90	Moderate Buy	$38.33	157.79% Upside

Current Analyst Ratings Breakdown

Latest AVMXY, IMVT, IBRX, and BCRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/20/2025	IBRX ImmunityBio	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$4.25 ➝ $5.00
5/12/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
5/12/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/7/2025	BCRX BioCryst Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $11.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $17.00
5/6/2025	BCRX BioCryst Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/5/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/29/2025	BCRX BioCryst Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$20.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVMXY AVITA MED LTD/S	$5.51M	118.31	N/A	N/A	$0.26 per share	30.35
BCRX BioCryst Pharmaceuticals	$503.49M	4.46	N/A	N/A	($2.22) per share	-4.83
IBRX ImmunityBio	$31.22M	75.48	N/A	N/A	($0.88) per share	-3.03
IMVT Immunovant	N/A	N/A	N/A	N/A	$2.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVMXY AVITA MED LTD/S	-$24.75M	-$0.39	N/A	∞	N/A	N/A	N/A	N/A	N/A
BCRX BioCryst Pharmaceuticals	-$226.54M	-$0.26	N/A	N/A	N/A	-30.01%	N/A	-24.06%	8/4/2025 (Estimated)
IBRX ImmunityBio	-$583.20M	-$0.58	N/A	N/A	N/A	-8,016.83%	N/A	-110.02%	8/11/2025 (Estimated)
IMVT Immunovant	-$259.34M	-$2.62	N/A	N/A	N/A	N/A	-77.94%	-69.82%	6/4/2025 (Estimated)

Latest AVMXY, IMVT, IBRX, and BCRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million
5/12/2025	Q1 2025	IBRX ImmunityBio	-$0.12	-$0.15	-$0.03	-$0.15	$17.50 million	$16.52 million
3/3/2025	Q4 2024	IBRX ImmunityBio	-$0.26	-$0.15	+$0.11	-$0.09	$8.74 million	$7.55 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVMXY AVITA MED LTD/S	N/A	N/A	N/A	N/A	N/A
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVMXY AVITA MED LTD/S	N/A	5.50	5.33
BCRX BioCryst Pharmaceuticals	N/A	2.78	2.73
IBRX ImmunityBio	N/A	2.68	2.64
IMVT Immunovant	N/A	6.04	6.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVMXY AVITA MED LTD/S	0.01%
BCRX BioCryst Pharmaceuticals	85.88%
IBRX ImmunityBio	8.58%
IMVT Immunovant	47.08%

Insider Ownership

Company	Insider Ownership
AVMXY AVITA MED LTD/S	N/A
BCRX BioCryst Pharmaceuticals	4.80%
IBRX ImmunityBio	76.79%
IMVT Immunovant	5.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVMXY AVITA MED LTD/S	55	82.62 million	N/A	Not Optionable
BCRX BioCryst Pharmaceuticals	530	209.25 million	197.19 million	Optionable
IBRX ImmunityBio	590	882.62 million	115.67 million	Optionable
IMVT Immunovant	120	169.86 million	159.84 million	Optionable

AVMXY, IMVT, IBRX, and BCRX Headlines

Recent News About These Companies

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $6.92 Million Stock Position in Immunovant, Inc. (NASDAQ:IMVT)

June 2 at 4:24 AM | marketbeat.com

HC Wainwright Estimates Immunovant FY2030 Earnings

June 2 at 2:42 AM | marketbeat.com

Leerink Partnrs Estimates Immunovant FY2030 Earnings

June 2 at 2:42 AM | marketbeat.com

Immunovant (NASDAQ:IMVT) Shares Gap Up Following Strong Earnings

May 31 at 1:19 AM | americanbankingnews.com

Immunovant (NASDAQ:IMVT) Shares Gap Up on Earnings Beat

May 30 at 10:05 AM | marketbeat.com

IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus

May 30 at 10:00 AM | zacks.com

Immunovant (NASDAQ:IMVT) Posts Earnings Results, Beats Expectations By $0.08 EPS

May 30 at 9:49 AM | marketbeat.com

Immunovant, Inc. Reports Strategic Progress and Financial Results

May 30 at 12:17 AM | tipranks.com

Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence

May 29, 2025 | msn.com

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025

May 29, 2025 | globenewswire.com

Immunovant (IMVT) to Release Earnings on Wednesday

May 29, 2025 | marketbeat.com

H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock

May 28, 2025 | msn.com

Immunovant (IMVT) Expected to Announce Earnings on Wednesday

May 28, 2025 | americanbankingnews.com

Nuveen Asset Management LLC Sells 189,759 Shares of Immunovant, Inc. (NASDAQ:IMVT)

May 26, 2025 | marketbeat.com

Bank of America Corp DE Buys 114,511 Shares of Immunovant, Inc. (NASDAQ:IMVT)

May 26, 2025 | marketbeat.com

Woodline Partners LP Sells 772,251 Shares of Immunovant, Inc. (NASDAQ:IMVT)

May 24, 2025 | marketbeat.com

Immunovant, Inc. (NASDAQ:IMVT) Shares Purchased by Two Seas Capital LP

May 23, 2025 | marketbeat.com

Rafferty Asset Management LLC Trims Stock Holdings in Immunovant, Inc. (NASDAQ:IMVT)

May 22, 2025 | marketbeat.com

IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm

May 21, 2025 | businesswire.com

Vestal Point Capital LP Makes New Investment in Immunovant, Inc. (NASDAQ:IMVT)

May 21, 2025 | marketbeat.com

Tyro Capital Management LLC Has $3.75 Million Stock Holdings in Immunovant, Inc. (NASDAQ:IMVT)

May 20, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVMXY, IMVT, IBRX, and BCRX Company Descriptions

AVITA MED LTD/S OTCMKTS:AVMXY

Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products for the treatment of burns, chronic wounds, and aesthetics indications. The company's patented and proprietary collection and application technology provides treatment solutions derived from a patient's own skin. Its lead product, RECELL System, is used in the treatment of various skin defects, such as burns and plastic reconstructive procedures. The company also offers ReGenerCell for chronic wounds and ReNovaCell for the restoration of pigmentation. Avita Medical Limited is based in Valencia, California.

BioCryst Pharmaceuticals NASDAQ:BCRX

$10.73 -0.15 (-1.38%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$10.86 +0.13 (+1.16%)

As of 08:27 AM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

ImmunityBio NASDAQ:IBRX

$2.67 +0.07 (+2.69%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$2.66 -0.02 (-0.56%)

As of 08:32 AM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Immunovant NASDAQ:IMVT

$14.87 -0.02 (-0.13%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$14.85 -0.02 (-0.13%)

As of 08:21 AM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time